Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

NCT00994253 · clinicaltrials.gov ↗
PHASE4
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.

Conditions

Interventions

Sponsor

Corewell Health East

Collaborators